Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Implementing universal vaccination programmes: USA

M Kane1

  • 1Global Programme for Vaccines, Division of Communicable Diseases, WHO, Geneva, Switzerland.

Vaccine
|January 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First Measurement of Time-Dependent CP Violation in the Flavor-Changing Neutral-Current Decay B^{0}→K_{S}^{0}μ^{+}μ^{-}.

Physical review letters·2026
Same author

Measurement of the Top-Quark Production Cross Section and Charge Asymmetry at LHCb.

Physical review letters·2026
Same author

Searches for B^{0}→K^{+}π^{-}τ^{+}τ^{-} and B_{s}^{0}→K^{+}K^{-}τ^{+}τ^{-} Decays.

Physical review letters·2026
Same author

First Evidence of the B_{s}^{0}→K^{-}π^{+}γ Decay.

Physical review letters·2026
Same author

Precision Measurement of CP Violation and Branching Fractions in B^{±}→K_{S}^{0}h^{±} (h=π, K) Decays and Search for the Rare Decay B_{c}^{±}→K_{S}^{0}K^{±}.

Physical review letters·2026
Same author

First Observation of the B[over ¯]_{s}^{0}→Λ_{c}^{+}Λ[over ¯]_{c}^{-} Decay and Evidence for the B[over ¯]^{0}→Λ_{c}^{+}Λ[over ¯]_{c}^{-} Decay.

Physical review letters·2026
Same journal

Immunogenicity and safety of a SARS-CoV-2 recombinant vaccine S-268024 booster vaccination versus NVX-CoV2373: Interim results from a phase 3, multicenter, randomized, observer-blind, active-controlled study.

Vaccine·2026
Same journal

Safety and immunogenicity of a reduced, homologous booster dose of the BNT162b2 mRNA COVID-19 vaccine: a single blind, randomized, non-inferiority follow-up trial.

Vaccine·2026
Same journal

Vaccination policies for healthcare personnel in Europe, 2026.

Vaccine·2026
Same journal

A historical overview of the anti-vaccine movement and its public health implications.

Vaccine·2026
Same journal

Vaccine strategies and development before and during the 1968 H3N2 influenza pandemic.

Vaccine·2026
Same journal

Influence of correlated vaccination behaviors on estimates of COVID-19 vaccine effectiveness in older adults - VISION network, October 2023 - March 2024.

Vaccine·2026
See all related articles

All US infants receive the hepatitis B vaccine (HBV) as part of routine immunizations, offering at least 10 years of protection without needing booster shots or pre-vaccination screening.

Area of Science:

  • Public Health
  • Immunology
  • Virology

Background:

  • The United States mandates hepatitis B virus (HBV) vaccination for all infants.
  • HBV vaccine integration into routine childhood schedules avoids extra healthcare visits.
  • Current policy does not recommend booster doses due to sustained protection for at least 10 years.

Purpose of the Study:

  • To summarize the current US policy on hepatitis B virus (HBV) vaccination for infants.
  • To highlight the integration of HBV vaccination into routine childhood immunization schedules.
  • To outline the approach to screening and immunization for HBV in pregnant women and newborns.

Main Methods:

  • Review of current US vaccination policies for hepatitis B virus (HBV).
  • Analysis of the rationale for not recommending booster doses.

Related Experiment Videos

  • Description of screening protocols for pregnant women and immunization of infants born to HBsAg-positive mothers.

    • Main Results:

    • Universal infant vaccination against HBV is standard practice in the USA.
    • The HBV vaccine is effectively integrated into routine childhood immunization schedules.
    • Screening of all pregnant women for HBsAg and immunizing infants of positive mothers continues.

    Conclusions:

    • The current US HBV vaccination policy ensures broad infant coverage.
    • The established vaccination schedule is efficient, requiring no additional visits.
    • Targeted screening and immunization strategies are maintained for high-risk infants.